Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 4/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.35 |
| ▸ | TRAP1 | Q12931 | 4/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17926576 | 0.85 | HSP90AA1 (0.39) | CYP1A2PDE2AHSP90AA1TRAP1HSP90AB1 | |
| SCHEMBL2786539 | 0.83 | PDE1A (0.42) | CYP1A2PDE2AHSP90AA1TRAP1HSP90AB1 | |
| SCHEMBL2804826 | 0.81 | PDE2A (0.39) | PDE2A | |
| SCHEMBL30095837 | 0.81 | PDE2A (0.39) | PDE2A | |
| SCHEMBL2241656 | 0.80 | SRC (0.44) | CYP1A2SMN1; SMN2ABL1 | |
| SCHEMBL30748233 | 0.80 | — | — | |
| SCHEMBL2189832 | 0.79 | ADORA3 (0.43) | CYP1A2SMN1; SMN2PDE2AHSP90AA1TRAP1 | |
| SCHEMBL11909416 | 0.78 | KMO (0.46) | SMN1; SMN2PDE2AHSP90AA1TRAP1HSP90AB1 | |
| SCHEMBL4451017 | 0.77 | ALDH1A1 (0.51) | CYP1A2SMN1; SMN2KMT2ACYP3A4CYP2D6 | |
| SCHEMBL7916660 | 0.77 | ALDH1A1 (0.41) | HSP90AA1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4115882-A1 | COMPOUNDS FOR IMPROVING MRNA SPLICING | The General Hospital Corporation (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-4115882-A1 | COMPOUNDS FOR IMPROVING MRNA SPLICING | The General Hospital Corporation (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-10676475-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2018-05-03 | — | — | US | disclosed |
| EP-3244891-A1 | COMPOUNDS FOR IMPROVING MRNA SPLICING | The General Hospital Corporation (US) | 2017-11-22 | — | — | EP | disclosed |
| WO-2016115434-A1 | COMPOUNDS FOR IMPROVING MRNA SPLICING | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016115434-A1 | COMPOUNDS FOR IMPROVING MRNA SPLICING | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-21 | — | — | WO | disclosed |
| EP-2382207-B1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING CO LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2010056320-A2 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | CYP1A2 4035/4885SMN1; SMN2 11/4885FSCN1 2602/4885 |
| US-10676475-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | CYP1A2 4035/4885SMN1; SMN2 11/4885FSCN1 2602/4885 |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | CYP1A2 4035/4885SMN1; SMN2 11/4885FSCN1 2602/4885 |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | CYP1A2 1944/4885SMN1; SMN2 2252/4885FSCN1 4815/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | CYP1A2 4035/4885SMN1; SMN2 11/4885FSCN1 2602/4885 |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | CYP1A2 4035/4885SMN1; SMN2 11/4885FSCN1 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.